Avanza Fonder’s Edwards Lifesciences EW Stock Holding History

Avanza Fonder’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6M	Sell	66,294 -971	-1%	-$81.3K	0.13%	152
2026 Q1	$5.39M	Sell	67,265 -5,778	-8%	-$476K	0.15%	137
2025 Q4	$6.23M	Buy	73,043 +1,309	+2%	+$107K	0.16%	126
2025 Q3	$5.58M	Buy	71,734 +9,173	+15%	+$717K	0.14%	126
2025 Q2	$4.89M	Sell	62,561 -141	-0.2%	-$10.5K	0.14%	124
2025 Q1	$4.52M	Sell	62,702 -2,740	-4%	-$196K	0.15%	128
2024 Q4	$4.84M	Buy	+65,442	New	+$4.58M	0.14%	123

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SIM

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

TIM

Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return

Avanza Fonder's EW Position: Q2 2026 in Review

Avanza Fonder reduced its Edwards Lifesciences (EW) stake by 1.4% in Q2 2026, selling an estimated $81.3K and leaving 66,294 shares worth $6M. The position accounts for 0.13% of the portfolio, ranked #152.

Avanza Fonder first reported a position in EW in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.23M in Q4 2025. 486 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Avanza Fonder held 66,294 shares of Edwards Lifesciences worth $6M as of Q2 2026.
Avanza Fonder sold 971 Edwards Lifesciences shares in Q2 2026, an estimated $81.3K.
Edwards Lifesciences made up 0.13% of Avanza Fonder's portfolio in Q2 2026, its #152 holding.
Avanza Fonder first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 7 quarters since.
Avanza Fonder's Edwards Lifesciences position peaked at $6.23M in Q4 2025.
486 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.